Ratings AstraZeneca PLC

Equities

Real-time Estimate Cboe Europe Other stock markets 11:13:07 23/06/2025 BST			5-day change	1st Jan Change
10,434.00 ^GBX	+0.40%		-3.57%	-0.34%

06-02	ASTRAZENECA : Buy rating from JP Morgan	ZD
06-02	UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	RE

The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

The company's enterprise value to sales, at 3.14 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company's earnings releases usually do not meet expectations.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ASTRAZENECA PLC				217B
	ELI LILLY AND COMPANY				685B
	JOHNSON & JOHNSON				360B
	NOVO NORDISK A/S				326B
	ROCHE HOLDING AG				255B
	NOVARTIS AG				228B
	MERCK & CO., INC.				199B
	AMGEN INC.				156B
	PFIZER, INC.				136B
	Average				284.55B
	Weighted average by Cap.